4D Molecular Therapeutics (FDMT) Proxy filing summary

Executive summary

• Annual meeting scheduled for June 17, 2026, to be held virtually for shareholder participation.

• Shareholders are encouraged to review proxy materials and vote on key proposals before the meeting.

Voting matters and shareholder proposals

• Election of three Class III directors to serve until the 2029 annual meeting or until successors are elected.

• Ratification of PricewaterhouseCoopers LLP as independent auditor for fiscal year ending December 31, 2026.

• Advisory, non-binding vote on executive compensation (say-on-pay).

• Proxies may vote on other business as may properly come before the meeting.

Board of directors and corporate governance

• Nominees for director positions include Nancy Miller-Rich, John F. Milligan, Ph.D., and Shawn Cline Tomasello, MBA.